SENATE BILL No. 287

DIGEST OF INTRODUCED BILL

Citations Affected: IC 16-18; IC 16-39-11; IC 21-14-1-1.5; IC 25-22.5; IC 25-26-13-4; IC 34-6-2-141.5; IC 34-13-3-1; IC 34-30-32; IC 34-30-33.

Synopsis: Health and immunization matters. Specifies that a state educational institution may not require an immunization passport. Provides that a state educational institution with a COVID-19 vaccine mandate is not entitled to certain statutory immunities. Specifies that the budget agency may not allot certain funds to a state educational institution that requires an immunization passport or has implemented a COVID-19 vaccine mandate. Makes it unlawful for the state or a political subdivision to spend public funds promoting a medical treatment for COVID-19. Prohibits discrimination on the basis of COVID-19 immunization status, prohibits requiring a person to answer a question concerning the person's COVID-19 immunization status, and limits the retention of medical records concerning COVID-19 immunization status. Prohibits the medical licensing board of Indiana or the Indiana board of pharmacy from taking disciplinary action against a physician or pharmacist based on the failure to follow guidelines, recommendations, or rules concerning COVID-19. Specifies that a physician noncompete agreement may not be enforced against a physician who suffers an adverse employment action due to the physician's opinion, recommendation, or treatment concerning COVID-19. Provides that a physician may not recommend that a child receive a COVID-19 immunization, and only authorizes a physician to administer a COVID-19 immunization if the physician provides: (1) a written document describing advantages and risks of a COVID-19 immunization; (2) the document is signed by the parent, guardian, health care representative, or emancipated child; and (3) the parent, guardian, health care representative, or emancipated child gives informed consent for the immunization.

Effective: July 1, 2022.

Zay

January 10, 2022, read first time and referred to Committee on Health and Provider Services.



Second Regular Session of the 122nd General Assembly (2022)

PRINTING CODE. Amendments: Whenever an existing statute (or a section of the Indiana Constitution) is being amended, the text of the existing provision will appear in this style type, additions will appear in this style type, and deletions will appear in this style type.

Additions: Whenever a new statutory provision is being enacted (or a new constitutional provision adopted), the text of the new provision will appear in **this style type**. Also, the word **NEW** will appear in that style type in the introductory clause of each SECTION that adds a new provision to the Indiana Code or the Indiana Constitution.

Conflict reconciliation: Text in a statute in *this style type* or *this style type* reconciles conflicts between statutes enacted by the 2021 Regular Session of the General Assembly.

SENATE BILL No. 287

A BILL FOR AN ACT to amend the Indiana Code concerning health.

Be it enacted by the General Assembly of the State of Indiana:

| 1 | SECTION 1. IC 16-18-1-6 IS ADDED TO THE INDIANA CODE |
|----|---|
| 2 | AS A NEW SECTION TO READ AS FOLLOWS [EFFECTIVE JULY |
| 3 | 1, 2022]: Sec. 6. It is unlawful for the state or a political subdivision |
| 4 | to: |
| 5 | (1) spend public funds promoting a medical treatment for |
| 6 | COVID-19; or |
| 7 | (2) offer a financial incentive or disincentive to an individual |
| 8 | for choosing or avoiding a particular medical treatment for |
| 9 | COVID-19. |
| 10 | SECTION 2. IC 16-18-2-338.4 IS ADDED TO THE INDIANA |
| 11 | CODE AS A NEW SECTION TO READ AS FOLLOWS |
| 12 | [EFFECTIVE JULY 1, 2022]: Sec. 338.4. "State", for purposes of |
| 13 | IC 16-39-11, has the meaning set forth in IC 16-39-11-4.5. |
| 14 | SECTION 3. IC 16-39-11-4.5 IS ADDED TO THE INDIANA |
| 15 | CODE AS A NEW SECTION TO READ AS FOLLOWS |
| 16 | [EFFECTIVE JULY 1, 2022]: Sec. 4.5. "State" includes a state |
| 17 | educational institution (as defined in IC 21-7-13-32). |
| | |



| 1 | SECTION 4. IC 16-39-11-5, AS ADDED BY P.L.196-2021, |
|----|--|
| 2 | SECTION 13, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE |
| 3 | JULY 1, 2022]: Sec. 5. (a) Except as provided in subsection (b), the |
| 4 | state or a local unit may not issue or require an immunization passport. |
| 5 | (b) This section does not prohibit the state or a local unit from doing |
| 6 | any of the following with the written permission of the individual: |
| 7 | (1) Maintaining, creating, or storing a medical record of an |
| 8 | individual's immunization status. |
| 9 | (2) Providing a medical record of an individual's immunization |
| 10 | status to the individual's medical provider in accordance with the |
| 11 | federal Health Insurance Portability and Accountability Act |
| 12 | (HIPAA) (P.L.104-191). |
| 13 | (3) Providing the individual with a record of an immunization at |
| 14 | the time the individual receives the immunization or upon request |
| 15 | by the individual. |
| 16 | (4) Maintaining an immunization record for the purpose of public |
| 17 | health administration. |
| 18 | SECTION 5. IC 16-39-11-6 IS ADDED TO THE INDIANA CODE |
| 19 | AS A NEW SECTION TO READ AS FOLLOWS [EFFECTIVE JULY |
| 20 | 1, 2022]: Sec. 6. (a) No person, including an insurer, may |
| 21 | discriminate against an individual based on the individual's |
| 22 | immunization status. |
| 23 | (b) Except for the purpose of medical diagnosis or treatment, no |
| 24 | person may require an individual to answer a question about the |
| 25 | individual's immunization status or discriminate against an |
| 26 | individual who does not answer a question about the individual's |
| 27 | immunization status. |
| 28 | (c) Except for the purpose of medical diagnosis or treatment, |
| 29 | and except as provided in section 5 of this chapter, no person may |
| 30 | retain records of an individual's immunization status. |
| 31 | (d) For purposes of: |
| 32 | (1) subsection (b), a question by an insurer is not made for the |
| 33 | purpose of medical diagnosis or treatment; and |
| 34 | (2) subsection (c), records held by an insurer are not for the |
| 35 | purpose of medical diagnosis or treatment. |
| 36 | (e) An individual may bring a civil action against a person who |
| 37 | violates this section. |
| 38 | (f) The court may award an individual who prevails in an action |
| 39 | under this section any of the following: |
| 40 | (1) Injunctive relief. |
| 41 | (2) The greater of: |
| 42 | (A) actual and consequential damages resulting from the |



| 1 | violation; or |
|----|---|
| 2 | (B) liquidated damages of not more than: |
| 3 | (i) five thousand dollars (\$5,000) for a first offense; and |
| 4 | (ii) ten thousand dollars (\$10,000) for a second or |
| 5 | subsequent offense. |
| 6 | (3) Costs and reasonable attorney's fees. |
| 7 | (4) Any other appropriate relief determined by the court. |
| 8 | SECTION 6. IC 16-39-11-7 IS ADDED TO THE INDIANA CODE |
| 9 | AS A NEW SECTION TO READ AS FOLLOWS [EFFECTIVE JULY |
| 10 | 1, 2022]: Sec. 7. (a) The state, a political subdivision, or a health |
| 11 | care provider may not make a recommendation concerning the |
| 12 | advisability of administering an immunization against COVID-19 |
| 13 | to a person less than eighteen (18) years of age. |
| 14 | (b) Except as provided in subsection (c), a physician may not |
| 15 | administer an immunization against COVID-19 to a child less than |
| 16 | eighteen (18) years of age unless: |
| 17 | (1) the physician provides the child's parent, guardian, or |
| 18 | health care representative with a written document that |
| 19 | neutrally describes: |
| 20 | (A) the advantages of administering an immunization |
| 21 | against COVID-19 to a child less than eighteen (18) years |
| 22 | of age; |
| 23 | (B) the risks of administering an immunization against |
| 24 | COVID-19 to a child less than eighteen (18) years of age; |
| 25 | and |
| 26 | (C) adverse reactions suffered by a child less than eighteen |
| 27 | (18) years of age who was administered an immunization |
| 28 | against COVID-19; |
| 29 | (2) after reading the document described in subdivision (1), |
| 30 | the parent, guardian, or health care representative signs the |
| 31 | document described in subdivision (1); and |
| 32 | (3) the parent, guardian, or health care representative gives |
| 33 | informed consent for the physician to administer an |
| 34 | immunization against COVID-19 to the child. |
| 35 | (c) This section applies only to a child less than eighteen (18) |
| 36 | years of age who is capable of consenting to the child's own health |
| 37 | care under IC 16-36-1-3(a)(2)(A), IC 16-36-1-3(a)(2)(B), |
| 38 | IC $16-36-1-3(a)(2)(C)$, IC $16-36-1-3(a)(2)(D)$, or |
| 39 | IC 16-36-1-3(a)(2)(F), and is not prohibited from consenting under |
| 40 | IC 16-36-1-4. A physician may not administer an immunization |
| 41 | against COVID-19 to a child to whom this section applies unless: |
| 42 | (1) the physician provides the child with a written document |



| 1 | |
|----|---|
| 1 | that neutrally describes: |
| 2 | (A) the advantages of administering an immunization |
| 3 | against COVID-19 to a child less than eighteen (18) years |
| 4 | of age; |
| 5 | (B) the risks of administering an immunization agains |
| 6 | COVID-19 to a child less than eighteen (18) years of age |
| 7 | and |
| 8 | (C) adverse reactions suffered by a child less than eighteen |
| 9 | (18) years of age who was administered an immunization |
| 10 | against COVID-19; |
| 11 | (2) the child signs the document described in subdivision (1) |
| 12 | and |
| 13 | (3) after reading and signing the document described in |
| 14 | subdivision (1), the child gives informed consent for the |
| 15 | physician to administer an immunization against COVID-19 |
| 16 | to the child. |
| 17 | SECTION 7. IC 21-14-1-1.5 IS ADDED TO THE INDIANA CODE |
| 18 | AS A NEW SECTION TO READ AS FOLLOWS [EFFECTIVE JULY |
| 19 | 1, 2022]: Sec. 1.5. (a) The following definitions apply throughout |
| 20 | this section: |
| 21 | (1) "Discretionary funds" has the meaning set forth in |
| 22 | IC 4-12-18-2. |
| 23 | (2) "Economic stimulus fund" refers to the economic stimulus |
| 24 | fund created by IC 4-12-18-4. |
| 25 | (3) "Immunization passport" has the meaning set forth in |
| 26 | IC 16-39-11-3. |
| 27 | (4) "State educational institution with a COVID-19 vaccine |
| 28 | mandate" has the meaning set forth in IC 34-30-32-5.5. |
| 29 | (b) If a state educational institution requires the use of ar |
| 30 | immunization passport, or is a state educational institution with a |
| 31 | COVID-19 vaccine mandate, the budget agency, after an advisory |
| 32 | recommendation from the budget committee, may not allot to and |
| 33 | shall withhold from the state educational institution all: |
| 34 | (1) discretionary funds in the economic stimulus fund; and |
| 35 | (2) funds appropriated by the general assembly to the state |
| 36 | educational institution for purposes of COVID-19 relief. |
| 37 | (c) If a state educational institution no longer requires the use |
| 38 | of an immunization passport, and is no longer a state educational |
| 39 | institution with a COVID-19 vaccine mandate, the budget agency |
| 40 | after an advisory recommendation from the budget committee |
| 41 | may allot the funds described in subsection (b). |

SECTION 8. IC 25-22.5-5.5-1, AS ADDED BY P.L.93-2020,



42

| 1 | SECTION 8, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE |
|----|---|
| 2 | JULY 1, 2022]: Sec. 1. (a) Except as provided in subsection (b), this |
| 3 | chapter applies to physician noncompete agreements originally entered |
| 4 | into on or after July 1, 2020. |
| 5 | (b) Section 2(b) of this chapter applies to a physician |
| 6 | noncompete agreement entered into or renewed after June 30, |
| 7 | 2022. |
| 8 | SECTION 9. IC 25-22.5-5.5-2, AS ADDED BY P.L.93-2020, |
| 9 | SECTION 8, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE |
| 10 | JULY 1, 2022]: Sec. 2. (a) Except as provided in subsection (b), to |
| 11 | be enforceable, a physician noncompete agreement must include all of |
| 12 | the following provisions: |
| 13 | (1) A provision that requires the employer of the physician to |
| 14 | provide the physician with a copy of any notice that: |
| 15 | (A) concerns the physician's departure from the employer; and |
| 16 | (B) was sent to any patient seen or treated by the physician |
| 17 | during the two (2) year period preceding the termination of the |
| 18 | physician's employment or the expiration of the physician's |
| 19 | contract. Provided, however, the patient names and contact |
| 20 | information be redacted from the copy of the notice provided |
| 21 | from the employer of the physician to the physician. |
| 22 | (2) A provision that requires the physician's employer to, in good |
| 23 | faith, provide the physician's last known or current contact and |
| 24 | location information to a patient who: |
| 25 | (A) requests updated contact and location information for the |
| 26 | physician; and |
| 27 | (B) was seen or treated by the physician during the two (2) |
| 28 | year period preceding the termination of the physician's |
| 29 | employment or the expiration of the physician's contract. |
| 30 | (3) A provision that provides the physician with: |
| 31 | (A) access to; or |
| 32 | (B) copies of; |
| 33 | any medical record associated with a patient described in |
| 34 | subdivision (1) or (2) upon receipt of the patient's consent. |
| 35 | (4) A provision that provides the physician whose employment |
| 36 | has terminated or whose contract has expired with the option to |
| 37 | purchase a complete and final release from the terms of the |
| 38 | enforceable physician noncompete agreement at a reasonable |
| 39 | price. However, in the event the physician elects not to exercise |
| 40 | the purchase option, then the option to purchase provision may |
| 41 | not be used in any manner to restrict, bar, or otherwise limit the |
| 42 | employer's equitable remedies, including the employer's |



| 1 | enforcement of the physician noncompete agreement. |
|----|--|
| 2 | (5) A provision that prohibits the providing of patient medical |
| 3 | records to a requesting physician in a format that materially |
| 4 | differs from the format used to create or store the medical record |
| 5 | during the routine or ordinary course of business, unless a |
| 6 | different format is mutually agreed upon by the parties. Paper or |
| 7 | portable document format copies of the medical records satisfy |
| 8 | the formatting provisions of this chapter. |
| 9 | (b) A physician noncompete agreement may not be enforced |
| 10 | against a physician if a person takes an adverse employment action |
| 11 | against a physician due to the physician's: |
| 12 | (1) opinion; |
| 13 | (2) statement; or |
| 14 | (3) treatment, nontreatment, or recommended treatment of a |
| 15 | person; |
| 16 | with respect to COVID-19. |
| 17 | SECTION 10. IC 25-22.5-6-5 IS ADDED TO THE INDIANA |
| 18 | CODE AS A NEW SECTION TO READ AS FOLLOWS |
| 19 | [EFFECTIVE JULY 1, 2022]: Sec. 5. The board may not take |
| 20 | disciplinary action against a physician licensed to practice |
| 21 | medicine or osteopathic medicine based on the physician's failure |
| 22 | or refusal to follow guidelines, recommendations, or rules relating |
| 23 | to COVID-19. |
| 24 | SECTION 11. IC 25-26-13-4, AS AMENDED BY P.L.5-2016, |
| 25 | SECTION 1, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE |
| 26 | JULY 1, 2022]: Sec. 4. (a) The board may: |
| 27 | (1) adopt rules under IC 4-22-2 for implementing and enforcing |
| 28 | this chapter; |
| 29 | (2) establish requirements and tests to determine the moral, |
| 30 | physical, intellectual, educational, scientific, technical, and |
| 31 | professional qualifications for applicants for pharmacists' |
| 32 | licenses; |
| 33 | (3) refuse to issue, deny, suspend, or revoke a license or permit or |
| 34 | place on probation or fine any licensee or permittee under this |
| 35 | chapter; |
| 36 | (4) regulate the sale of drugs and devices in the state of Indiana; |
| 37 | (5) impound, embargo, confiscate, or otherwise prevent from |
| 38 | disposition any drugs, medicines, chemicals, poisons, or devices |
| 39 | which by inspection are deemed unfit for use or would be |
| 40 | dangerous to the health and welfare of the citizens of the state of |
| 41 | Indiana; the board shall follow those embargo procedures found |

in IC 16-42-1-18 through IC 16-42-1-31, and persons may not



42

| | 1 |
|---|--|
| 1 | refuse to permit or otherwise prevent members of the board or |
| 2 | their representatives from entering such places and making such |
| 3 | inspections; |
| 4 | (6) prescribe minimum standards with respect to physical |
| 5 | characteristics of pharmacies, as may be necessary to the |
| 6 | maintenance of professional surroundings and to the protection of |
| 7 | the safety and welfare of the public; |
| 8 | (7) subject to IC 25-1-7, investigate complaints, subpoena |
| Ω | with a same and a dula and a surduct beautions on behalf of the multi- |

- witnesses, schedule and conduct hearings on behalf of the public interest on any matter under the jurisdiction of the board;
- (8) prescribe the time, place, method, manner, scope, and subjects of licensing examinations which shall be given at least twice annually; and
- (9) perform such other duties and functions and exercise such other powers as may be necessary to implement and enforce this chapter.
- (b) The board shall adopt rules under IC 4-22-2 for the following:
 - (1) Establishing standards for the competent practice of pharmacy.
 - (2) Establishing the standards for a pharmacist to counsel individuals regarding the proper use of drugs.
 - (3) Establishing standards and procedures before January 1, 2006, to ensure that a pharmacist:
 - (A) has entered into a contract that accepts the return of expired drugs with; or
 - (B) is subject to a policy that accepts the return of expired drugs of;
 - a wholesaler, manufacturer, or agent of a wholesaler or manufacturer concerning the return by the pharmacist to the wholesaler, the manufacturer, or the agent of expired legend drugs or controlled drugs. In determining the standards and procedures, the board may not interfere with negotiated terms related to cost, expenses, or reimbursement charges contained in contracts between parties, but may consider what is a reasonable quantity of a drug to be purchased by a pharmacy. The standards and procedures do not apply to vaccines that prevent influenza, medicine used for the treatment of malignant hyperthermia, and other drugs determined by the board to not be subject to a return policy. An agent of a wholesaler or manufacturer must be appointed in writing and have policies, personnel, and facilities to handle properly returns of expired legend drugs and controlled substances.



| 1 | (c) The board may grant or deny a temporary variance to a rule it |
|----|---|
| 2 | has adopted if: |
| 3 | (1) the board has adopted rules which set forth the procedures and |
| 4 | standards governing the grant or denial of a temporary variance; |
| 5 | and |
| 6 | (2) the board sets forth in writing the reasons for a grant or denial |
| 7 | of a temporary variance. |
| 8 | (d) The board shall adopt rules and procedures, in consultation with |
| 9 | the medical licensing board, concerning the electronic transmission of |
| 10 | prescriptions. The rules adopted under this subsection must address the |
| 11 | following: |
| 12 | (1) Privacy protection for the practitioner and the practitioner's |
| 13 | patient. |
| 14 | (2) Security of the electronic transmission. |
| 15 | (3) A process for approving electronic data intermediaries for the |
| 16 | electronic transmission of prescriptions. |
| 17 | (4) Use of a practitioner's United States Drug Enforcement |
| 18 | Agency registration number. |
| 19 | (5) Protection of the practitioner from identity theft or fraudulent |
| 20 | use of the practitioner's prescribing authority. |
| 21 | (e) The governor may direct the board to develop: |
| 22 | (1) a prescription drug program that includes the establishment of |
| 23 | criteria to eliminate or significantly reduce prescription fraud; and |
| 24 | (2) a standard format for an official tamper resistant prescription |
| 25 | drug form for prescriptions (as defined in IC 16-42-19-7(1)). |
| 26 | The board may adopt rules under IC 4-22-2 necessary to implement |
| 27 | this subsection. |
| 28 | (f) The standard format for a prescription drug form described in |
| 29 | subsection (e)(2) must include the following: |
| 30 | (1) A counterfeit protection bar code with human readable |
| 31 | representation of the data in the bar code. |
| 32 | (2) A thermochromic mark on the front and the back of the |
| 33 | prescription that: |
| 34 | (A) is at least one-fourth (1/4) of one (1) inch in height and |
| 35 | width; and |
| 36 | (B) changes from blue to clear when exposed to heat. |
| 37 | (g) The board may contract with a supplier to implement and |
| 38 | manage the prescription drug program described in subsection (e). The |
| 39 | supplier must: |
| 40 | (1) have been audited by a third party auditor using the SAS 70 |
| 41 | audit or an equivalent audit for at least the three (3) previous |
| | man of an equivalent agait for at least the times (3) previous |



years; and

| (2) be audited by a third party auditor using the SAS 70 audit or |
|---|
| an equivalent audit throughout the duration of the contract; |
| in order to be considered to implement and manage the program. |
| (h) The board shall adopt rules under IC 4-22-2, or emergency rules |
| in the manner provided under IC 4-22-2-37.1 that take effect on July 1, |
| 2016, concerning: |
| (1) professional determinations made under IC 35-48-4-14.7(d); |
| and |
| (2) the determination of a relationship on record with the |
| pharmacy under IC 35-48-4-14.7. |
| (i) The board may: |
| (1) review professional determinations made by a pharmacist; and |
| (2) except as otherwise provided in this section, take |
| appropriate disciplinary action against a pharmacist who violates |
| a rule adopted under subsection (h) concerning a professional |
| determination made; |
| under IC 35-48-4-14.7 concerning the sale of ephedrine and |
| pseudoephedrine. |
| (j) The board may not take disciplinary action against a |
| pharmacist based on the pharmacist's failure or refusal to follow |
| guidelines, recommendations, or rules relating to COVID-19. |
| SECTION 12. IC 34-6-2-141.5 IS ADDED TO THE INDIANA |
| CODE AS A NEW SECTION TO READ AS FOLLOWS |
| [EFFECTIVE JULY 1, 2022]: Sec. 141.5. "State educational |
| institution with a COVID-19 vaccine mandate", for purposes of |
| IC 34-30-32 and IC 34-30-33, has the meaning set forth in |
| IC 34-30-32-5.5. |
| SECTION 13. IC 34-13-3-1 IS AMENDED TO READ AS |
| FOLLOWS [EFFECTIVE JULY 1, 2022]: Sec. 1. (a) This chapter |
| does not apply to a claim or cause of action: |
| (1) arising from COVID-19 (as defined in IC 34-30-32-2); or |
| (2) relating to harm from a COVID-19 protective product (as |
| defined in IC 34-30-33-2); |
| against a state educational institution with a COVID-19 vaccine |
| mandate (as defined in IC 34-30-32-5.5). |
| (a) (b) This chapter applies only to a claim or suit in tort. |
| (b) (c) The provisions of this chapter also apply to IC 34-30-14. |
| SECTION 14. IC 34-30-32-1, AS ADDED BY P.L.1-2021, |
| SECTION 7, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE |
| JULY 1, 2022]: Sec. 1. (a) This chapter does not apply to a state |
| educational institution with a COVID-19 vaccine mandate. |
| |

(a) (b) This chapter applies only to a tort action.



42

| (b) (c) This chapter applies to a cause of action that accrues on or |
|--|
| after March 1, 2020. |
| SECTION 15. IC 34-30-32-5.5 IS ADDED TO THE INDIANA |
| CODE AS A NEW SECTION TO READ AS FOLLOWS |
| [EFFECTIVE JULY 1, 2022]: Sec. 5.5. As used in this chapter, "state |
| educational institution with a COVID-19 vaccine mandate" means |
| a state educational institution (as defined in IC 21-7-13-32) that |
| requires a student to be vaccinated against COVID-19 as a |
| condition of attending a class in person, regardless of whether |
| medical, religious, or other exemptions are available to a student. |
| SECTION 16. IC 34-30-33-1, AS ADDED BY P.L.1-2021, |
| SECTION 8, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE |
| JULY 1, 2022]: Sec. 1. (a) This chapter does not apply to a state |
| educational institution with a COVID-19 vaccine mandate. |
| (b) This chapter only applies to a tort action. |
| SECTION 17. IC 34-30-33-2, AS ADDED BY P.L.1-2021, |
| SECTION 8, IS AMENDED TO READ AS FOLLOWS [EFFECTIVE |
| JULY 1, 2022]: Sec. 2. The following definitions apply throughout this |
| chapter: |
| (1) "COVID-19" means: |
| (A) severe acute respiratory syndrome coronavirus 2 or a |
| |
| mutated form of severe acute respiratory syndrome |
| mutated form of severe acute respiratory syndrome coronavirus 2; or |
| |
| coronavirus 2; or |
| coronavirus 2; or (B) the disease caused by severe acute respiratory syndrome |
| coronavirus 2; or (B) the disease caused by severe acute respiratory syndrome coronavirus 2 or a mutated form of severe acute respiratory |
| coronavirus 2; or (B) the disease caused by severe acute respiratory syndrome coronavirus 2 or a mutated form of severe acute respiratory syndrome coronavirus 2. |
| coronavirus 2; or (B) the disease caused by severe acute respiratory syndrome coronavirus 2 or a mutated form of severe acute respiratory syndrome coronavirus 2. (2) "COVID-19 protective product" means one (1) or more of the |
| coronavirus 2; or (B) the disease caused by severe acute respiratory syndrome coronavirus 2 or a mutated form of severe acute respiratory syndrome coronavirus 2. (2) "COVID-19 protective product" means one (1) or more of the following: |
| coronavirus 2; or (B) the disease caused by severe acute respiratory syndrome coronavirus 2 or a mutated form of severe acute respiratory syndrome coronavirus 2. (2) "COVID-19 protective product" means one (1) or more of the following: (A) Personal protective equipment. |
| coronavirus 2; or (B) the disease caused by severe acute respiratory syndrome coronavirus 2 or a mutated form of severe acute respiratory syndrome coronavirus 2. (2) "COVID-19 protective product" means one (1) or more of the following: (A) Personal protective equipment. (B) Medical devices, equipment, and supplies used to treat |
| coronavirus 2; or (B) the disease caused by severe acute respiratory syndrome coronavirus 2 or a mutated form of severe acute respiratory syndrome coronavirus 2. (2) "COVID-19 protective product" means one (1) or more of the following: (A) Personal protective equipment. (B) Medical devices, equipment, and supplies used to treat COVID-19, including medical devices, equipment, or supplies |
| coronavirus 2; or (B) the disease caused by severe acute respiratory syndrome coronavirus 2 or a mutated form of severe acute respiratory syndrome coronavirus 2. (2) "COVID-19 protective product" means one (1) or more of the following: (A) Personal protective equipment. (B) Medical devices, equipment, and supplies used to treat COVID-19, including medical devices, equipment, or supplies that are used or modified for an unapproved use to treat |
| coronavirus 2; or (B) the disease caused by severe acute respiratory syndrome coronavirus 2 or a mutated form of severe acute respiratory syndrome coronavirus 2. (2) "COVID-19 protective product" means one (1) or more of the following: (A) Personal protective equipment. (B) Medical devices, equipment, and supplies used to treat COVID-19, including medical devices, equipment, or supplies that are used or modified for an unapproved use to treat COVID-19 or to prevent the spread of COVID-19. |
| coronavirus 2; or (B) the disease caused by severe acute respiratory syndrome coronavirus 2 or a mutated form of severe acute respiratory syndrome coronavirus 2. (2) "COVID-19 protective product" means one (1) or more of the following: (A) Personal protective equipment. (B) Medical devices, equipment, and supplies used to treat COVID-19, including medical devices, equipment, or supplies that are used or modified for an unapproved use to treat COVID-19 or to prevent the spread of COVID-19. (C) Medical devices, equipment, and supplies used outside of |
| coronavirus 2; or (B) the disease caused by severe acute respiratory syndrome coronavirus 2 or a mutated form of severe acute respiratory syndrome coronavirus 2. (2) "COVID-19 protective product" means one (1) or more of the following: (A) Personal protective equipment. (B) Medical devices, equipment, and supplies used to treat COVID-19, including medical devices, equipment, or supplies that are used or modified for an unapproved use to treat COVID-19 or to prevent the spread of COVID-19. (C) Medical devices, equipment, and supplies used outside of their normal use to treat COVID-19 or to prevent the spread of |
| coronavirus 2; or (B) the disease caused by severe acute respiratory syndrome coronavirus 2 or a mutated form of severe acute respiratory syndrome coronavirus 2. (2) "COVID-19 protective product" means one (1) or more of the following: (A) Personal protective equipment. (B) Medical devices, equipment, and supplies used to treat COVID-19, including medical devices, equipment, or supplies that are used or modified for an unapproved use to treat COVID-19 or to prevent the spread of COVID-19. (C) Medical devices, equipment, and supplies used outside of their normal use to treat COVID-19 or to prevent the spread of COVID-19. |
| coronavirus 2; or (B) the disease caused by severe acute respiratory syndrome coronavirus 2 or a mutated form of severe acute respiratory syndrome coronavirus 2. (2) "COVID-19 protective product" means one (1) or more of the following: (A) Personal protective equipment. (B) Medical devices, equipment, and supplies used to treat COVID-19, including medical devices, equipment, or supplies that are used or modified for an unapproved use to treat COVID-19 or to prevent the spread of COVID-19. (C) Medical devices, equipment, and supplies used outside of their normal use to treat COVID-19 or to prevent the spread of COVID-19. (D) Medications used to treat COVID-19, including |
| coronavirus 2; or (B) the disease caused by severe acute respiratory syndrome coronavirus 2 or a mutated form of severe acute respiratory syndrome coronavirus 2. (2) "COVID-19 protective product" means one (1) or more of the following: (A) Personal protective equipment. (B) Medical devices, equipment, and supplies used to treat COVID-19, including medical devices, equipment, or supplies that are used or modified for an unapproved use to treat COVID-19 or to prevent the spread of COVID-19. (C) Medical devices, equipment, and supplies used outside of their normal use to treat COVID-19 or to prevent the spread of COVID-19. (D) Medications used to treat COVID-19, including medications prescribed or dispensed for off label use to |
| |

exposure to COVID-19.



42

| 1 | (F) A product designed to clean or disinfect to prevent the |
|---|---|
| 2 | spread of COVID-19. |
| 3 | (G) Any component of an item described in this subdivision. |
| 4 | (3) "Manufacturer or supplier" means a person who designs, |
| 5 | manufactures, labels, sells, distributes, or donates a COVID-19 |
| 6 | protective product. |
| 7 | (4) "State educational institution with a COVID-19 vaccine |
| 8 | mandate" has the meaning set forth in IC 34-30-32-5.5 |

